UCB received approval from the U.S. Food and Drug Administration (FDA) for a label extension for the company’s anti-epileptic drug, VIMPAT (lacosamide) CV, as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older.
 
This new approval provides clinicians with the option to prescribe VIMPAT to their pediatric patients either as an oral solution or a convenient tablet. The treatment further helps medical professionals support the U.S. pediatric epilepsy community in managing childhood epilepsy, addressing a paucity of medicines approved for this patient population. 
 
“Although there are many children and families severely affected by epilepsy, until recently there were few effective treatment options approved for childhood epilepsy. This has contributed to poor seizure control for many, which can be detrimental to overall quality-of-life,” said Dr. Raman Sankar, MD, PhD, professor of Neurology and Pediatrics and chief of Pediatric Neurology at the David Geffen School of Medicine at the University of California, Los Angeles. “The availability of VIMPAT for children with epilepsy has the potential to change the lives of children and their families by providing an additional choice to support them in their epilepsy journey.”
 
VIMPAT is approved in 72 countries worldwide.